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Abstract
IMPORTANCE The blood pressure–lowering property of docosahexaenoic acid (DHA) in children
and adults is known, and an observational study from the Netherlands has linked higher intrauterine
DHA exposure to lower childhood blood pressure. However, the association of prenatal intake of
DHA supplement with childhood blood pressure has not been evaluated in randomized clinical trials.
OBJECTIVE To determine the effect of DHA supplementation during pregnancy on childhood blood
pressure.
DESIGN, SETTING, AND PARTICIPANTS This prespecified secondary analysis of the Kansas
University DHA Outcome Study (KUDOS), a phase 3, double-blind, randomized, placebo-controlled
clinical trial was conducted at several local hospitals in the Kansas City, Kansas, metropolitan area.
Pregnant women (n = 350) were enrolled in the KUDOS trial between January 10, 2006, and
November 17, 2009, and were followed up until their children were 18 months of age. During
pregnancy, the women received either 3 capsules per day of placebo or 600 mg per day of DHA from
a mean (SD) of 14.5 (3.7) weeks’ (all before 20 weeks) gestation until birth. The parents of 190
children consented to additional follow-up of their children until 6 years, which ended April 29, 2016.
Study personnel involved in testing were blind to the randomization until all children had completed
the trial. Data analysis was performed from May 23, 2017, to July 10, 2018.
INTERVENTIONS Pregnant women were assigned to either 600 mg per day of DHA or a placebo
that was half soy and half corn oil. Both placebo and DHA were provided in 3 capsules per day.
MAIN OUTCOMES AND MEASURES Childhood blood pressure was a planned secondary outcome
of a study powered to measure cognitive development. The hypothesis was that DHA would lower
blood pressure prior to data analysis. Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured at 4, 4.5, 5, 5.5, and 6 years and were analyzed for possible covariates using
mixed models to generate a final model.
RESULTS In total, 171 children (88 [51.5%] female) were included in this analysis. Of these children,
89 (52.0%) were randomized to the DHA group and 82 (47.9%) to the placebo group. A statistically
significant interaction was found between treatment (placebo or DHA) and child weight status
(5-year body mass index 85th or >85th percentile) for both SBP and DBP. Children who were
overweight or obese whose mothers received placebo during pregnancy had higher SBP and DBP
compared with children who were overweight or obese whose mothers received DHA (mean [SE]
SBP, 104.28 [1.37] mm Hg vs 100.34 [1.02] mm Hg; DBP, 64.7 [1.23] mm Hg vs 59.76 [0.91] mm Hg).
No differences in the SBP and DBP were found between children who were overweight or obese
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Key Points
Question Is maternal intake of prenatal
docosahexaenoic acid associated with
reductions in childhood blood pressure?
Findings In this prespecified secondary
analysis of a randomized clinical trial and
follow-up of 171 mothers and their
offspring, the children of women
randomized to receive prenatal
docosahexaenoic acid did not
experience an increase in systolic blood
pressure and diastolic blood pressure
if they became overweight or obese
compared with children of women
randomized to placebo. A statistically
significant interaction was found
between prenatal treatment and child
weight status.
Meaning Docosahexaenoic acid intake
during pregnancy may protect children
from the blood pressure–elevating
consequence of childhood overweight
condition or obesity.
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Abstract (continued)
whose mothers received DHA and children who were not overweight or obese. In the mixed model
analysis, the child’s age at blood pressure measurement and the maternal prepregnancy body mass
index were the only other statistically significant variables (child age, SBP: F = 7.385; P = .001; DBP:
F = 7.39; P = .001; prepregnancy BMI, SBP: r = 0.284; P = .001; DBP: r = 0.216; P = .01).
CONCLUSIONS AND RELEVANCE Maternal docosahexaenoic acid intake during pregnancy
appeared to mitigate the association between childhood overweight condition or obesity and blood
pressure.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02487771
JAMA Network Open. 2019;2(2):e190088. doi:10.1001/jamanetworkopen.2019.0088
Introduction
Consumption of docosahexaenoic acid (DHA) and eicosapentaenoic acid from fish oil is well known
to reduce blood pressure (BP) in both adults and children.1,2 However, there has been recent interest
in the potential programming association of DHA in utero and in early infancy with long-term
physiological functions, including BP. Consistent with this possibility, a large population-based
prospective cohort study from the Netherlands found an association between higher in utero DHA
exposure and lower systolic BP (SBP) at age 6 years.3,4 Another 4-country European study found
lower diastolic BP (DBP) at age 6 years in children randomized to an infant formula containing DHA
for only the first 4 months of infancy.5
Only randomized clinical trials of DHA supplementation during pregnancy can determine if
improving DHA nutrition during fetal life improves childhood BP. The Kansas University DHA
Outcome Study (KUDOS) trial randomized pregnant women to either a DHA supplement of 600 mg
per day or a placebo and followed up the growth and development of their offspring to 6 years of
age. The follow-up included semiannual BP measurements from 4 to 6 years of age among 179
children (92 DHA and 87 placebo recipients) as an indicator of child health. Based on the findings of
Forsyth et al,5 we hypothesized that maternal DHA supplementation would be associated with
reductions in BP in childhood. Results from this randomly exposed cohort agree with those of the
Forsyth et al5 report and 2 recent reports,3,4 suggesting that prenatal DHA exposure is associated
with reductions in childhood BP; however, this report suggests that children who become
overweight or obese are the ones protected from higher BP by maternal DHA supplementation.
Methods
The University of Kansas Institutional Review Board approved this prespecified secondary analysis
and both the parent randomized clinical trials, KUDOS (NCT00266825)6 and its follow-up
(NCT02487771). The trial protocol is available as Supplement 1. Both the research protocol and written
informed consent adhered to the Declaration of Helsinki.7 This study followed the Consolidated
Standards of Reporting Trials (CONSORT) reporting guideline.
Participants
From January 10, 2006, through November 17, 2009, 350 pregnant women were enrolled in the
KUDOS trial, a phase 3, double-blind, randomized, placebo-controlled clinical trial of DHA
supplementation delivered at several local hospitals in the Kansas City, Kansas, metropolitan area.
Women were randomized to either placebo (3 capsules per day containing an equal mixture of
soybean and corn oil) or DHA (3 capsules per day of algal oil that provided a total of 600 mg of DHA).
Randomization schedules generated by the biostatistics department were for 2 maternal age groups
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(16-25.99 years and 26-35.99 years). Each 8–random number sequence included 4 assignments per
group stratified by treatment. The Investigational Pharmacy at the University of Kansas Medical
Center assigned women to placebo or DHA on the basis of age shared by study personnel. Both the
placebo and DHA capsules were orange flavored and provided by DSM Nutritional Products. Women
were enrolled at a mean (SD) of 14.5 (3.7) weeks’ gestation but had to be enrolled before 20 weeks’
gestation. The primary aims of the KUDOS trial were to evaluate the effect of prenatal DHA
supplement of 600 mg per day, compared with placebo, on pregnancy outcomes and infant
development to age 18 months.
When children were 18 months of age, the parents of 190 children gave permission for
continued follow-up, which included longitudinal assessments of diet, cognitive development, BP,
and growth to 6 years of age. Parents who consented to follow-up into childhood differed from those
who consented to the KUDOS trial in that the mothers were approximately 1 year older at enrollment
(26.2 vs 25.0 years), less likely to be black individuals (29.5% vs 41.5%), and more likely to be
compliant with capsule intake (consuming a mean [SD] of 428 [117] vs 362 [150] capsules during the
primary study).6 The follow-up study (conducted from July 17, 2008, to April 29, 2016) was powered
on the primary aim of evaluating cognitive development. Dietary intake, growth, and BP were its
secondary outcomes. Eleven of the 190 children (5.8%) were lost to follow-up before BP assessment
began at 4 years of age. An additional 8 children did not have a body mass index assessment at 5
years of age. Thus, this secondary analysis included 171 children (Figure 1).
The principal investigator of the KUDOS trial (S.E.C.) was unblinded to report the results of
pregnancy outcome after completion of the parent trial; however, all other study personnel remained
blind to the randomization until after the results were entered for the last child who reached 6 years
of age. Blood pressure was measured semiannually from 4 years through 6 years of age.
Anthropometric assessment and 24-hour dietary recalls were obtained at each visit from birth to age
6 years. Inclusion and exclusion criteria of the KUDOS trial ensured that women did not have any
health issue that could increase the risk for adverse effects on offspring growth and development.
Exclusion criteria included preexisting diabetes, hypertension, HIV/AIDs, hepatitis, lupus, cancer,
Figure 1. CONSORT Flow Diagram
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alcohol or other drug dependency, and BMI higher than 40 at the time of enrollment into the trial.
Other details of study design and demographic characteristics were included in a report of pregnancy
outcome.6 Information on childhood diet8 and 5-year body composition of the offspring9 has also
been reported.
Anthropometric Assessment
Height was measured without shoes to the nearest 0.1 cm using a wall-mounted stadiometer (Health
O Meter; PORTROD). Body weight was obtained to the nearest 0.01 kg using the system integrated
electronic scale. Anthropometric data were converted to BMI percentiles with Epi Info, version 3.5.4
(Centers for Disease Control and Prevention).
Dietary Intake
A registered dietitian (E.H.K., J.M.T., or J.M.H.) trained in the multipass 24-hour dietary recall method
and neutral probing questions interviewed parents about their child’s food intake at each visit
throughout the KUDOS and follow-up trials. Multiple dietary recalls have been shown to represent
usual dietary intakes.10 During infancy, the child’s dietary recalls were collected at 6 weeks and 4, 6,
9, and 12 months as well as from ages 1 to 6 years at 6-month intervals. Recalls were entered into the
Nutrition Data System for Research, version 2008-2014 (University of Minnesota) and evaluated for
accuracy by a second registered dietitian (one of E.H.K, J.M.T., or J.M.H.). If the parent or child was
unable to recall 1 or more meals in a 24-hour period, the recall was excluded from analysis. The mean
results of all 24-hour recalls obtained between 1 and 5 years of age were calculated to estimate the
dietary sodium intake (grams per 1000 kcal).
Blood Pressure Measurement
We measured childhood BP using an automated system (CARESCAPE V100 Monitor; GE), with the
cuff size recommended for the child’s arm circumference. Blood pressure was measured in triplicate:
the mean of the last 2 measures for SBP and DBP was taken unless the coefficient of variance was
greater than 0.095. If the coefficient of variance was greater than 0.095 (9.2% of SBP and 19.4% of
DBP measurements), we used the mean of the 2 closest measurements for each indicator. We
excluded from analysis the results of assessments with only 1 reliable data point (n = 23). Irritated or
restless children or mechanical failure were the main reasons for exclusion. Members of the staff
who measured BP and made decisions related to data quality and calculations were blinded to the
mothers’ study randomization.
Statistical Analysis
Data analysis was performed (J.W. and J.C.) from May 23, 2017, to July 10, 2018. Children’s SBP and
DBP measured at 4, 4.5, 5, 5.5, and 6 years of age were the dependent variables for this study. We
conducted a type 3 test of fixed effects to test for the association of maternal randomization
(placebo or DHA) and other independent variables with BP. Birth weight, mean sodium intake per
1000 kcal, days fed human milk, maternal gestational weight gain, and race and days smoked during
pregnancy were eliminated as influential covariates. The secondary mixed model analysis included
maternal DHA randomization, child weight status (BMI 85th or >85th percentile) at 5 years of age,
child visit or age at assessment (4, 4.5, 5, 5.5, or 6 years), socioeconomic status, maternal
prepregnancy BMI, and additional DHA supplements taken during pregnancy. The number of
children studied and the number of valid BP assessments obtained at each age are shown in the
eTable in Supplement 2. We chose weight status at 5 years of age because our analysis showed that
children who were obese or overweight at age 5 years were, as a group, obese or overweight at 4 and
6 years of age. Two-sided P  .05 for a 2-tailed analysis was considered statistically significant.
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Results
In total, 171 children (88 [51.5%] female) were included in this analysis. Of these children, 89 (52.0%)
were randomized to the DHA group and 82 (47.9%) to the placebo group. The characteristics of
children in the maternal randomization groups by weight status (BMI 85th or >85th percentile) are
included in Table 1.
Similar to those in the KUDOS trial cohort,6 children in the DHA group had a higher mean (SD)
birth weight compared with the placebo group (birth weight: 3441 [485] g vs 3266 [522] g) (Table 1).
Mothers of children who were overweight or obese in both treatment groups had a higher mean (SD)
number of days of smoking during pregnancy (days smoking: 62 [106] d vs 45 [94] d). Mothers in
the placebo group with children who were obese or overweight provided fewer mean (SD) number
of days of human milk (BMI >85th percentile, 137 [161] days vs 202 [285] days) and their children
consumed a higher mean (SD) amount of sodium (BMI >85th percentile, 2301 [609] mg/d vs 2002
[470] mg/d) compared with the DHA group that was obese or overweight (Table 1). However, it was
apparent from examining the large variability in both human milk feeding and sodium intake that
these differences were not statistically significant. In addition, our preliminary analysis eliminated
these factors as important to childhood BP.
Secondary Analyses
We tested a model for SBP and DBP that included maternal DHA randomization, child age and sex,
and child BMI (85th or >85th percentile) at 5 years of age as well as important covariates
(socioeconomic status, maternal BMI, and additional supplemental DHA taken during pregnancy).
The aim of this analysis was to determine whether these additional factors mediated BP outcomes.
Analyses of SBP yielded a marginal effect for DHA group and a substantial main effect for BMI
(85th or >85th percentile). These associations were quantified by a statistically significant P for
interaction = .04 (Table 2). Children who were obese or overweight (with a 5-year BMI >85th
percentile) whose mothers were randomized to the placebo group had a mean (SE) SBP of 104.28
(1.37) mm Hg compared with obese or overweight children in the DHA group (100.34 [1.02]), a
difference of 3.94 mm Hg. Maternal prepregnancy BMI was a statistically significant covariate with
higher BMI associated with higher childhood BP (r = 0.284, P = .001). The analysis also yielded a
statistically significant main effect for child age as SBP was higher at 5.5 years of age than any other
age (F = 7.385; P = .001). For example, BP at 5.5 years in overweight condition and obese children in
Table 1. Child Characteristics by Maternal Docosahexaenoic Acid (DHA) Randomization
and 5-Year Weight Statusa
Variable
No. (%)









Sample size, No. (%) 20 (24) 62 (76) 32 (36) 57 (64)
Sodium intake, mean (SD), mg/d 2301 (609) 2016 (483) 2002 (470) 2028 (643)
BMI percentile, mean (SD)
2 y 81 (28) 51 (27) 82 (15) 57 (23)
3 y 83 (16) 53 (24) 88 (12) 55 (25)
4 y 90 (9) 53 (24) 91 (7) 59 (26)
5 y 95 (4) 54 (22) 93 (4) 56 (22)
6 y 94 (5) 53 (23) 92 (7) 56 (24)
Human milk intake, mean (SD), d 137 (161) 206 (240) 202 (285) 213 (231)
Male, No. (%) 13 (65) 33 (53) 11 (34) 26 (46)
Female, No. (%) 7 (35) 29 (47) 21(66) 31(54)
Smoking during pregnancy, mean (SD), d 68 (102) 46 (96) 58 (108) 45 (94)
Prepregnancy BMI, mean (SD), kg/cm2 24.6 (4) 25.6 (5) 26.7 (5) 25.8 (5)
Birth weight, mean (SD), g 3381 (542) 3218 (511) 3447 (444) 3457 (515)
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); DHA, docosahexaenoic acid.
a No statistical comparisons were made.
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the placebo group was 110 (2.3) mm Hg compared with 4, 4.5, 5, and 6 years (101 [2.4], 103 [1.9], 104
[1.6], and 106 [1.8] mm Hg, respectively). The SBP and variability for each age by randomization and
weight status are shown in Figure 2A.
Analysis of DBP yielded statistically significant main effects for the DHA group and BMI. These
associations were quantified by a statistically significant interaction (Table 2), such that children who
were obese or overweight had higher DBP only if their mothers did not receive the DHA supplement
during pregnancy. Children who were obese or overweight (with a 5-year BMI >85th percentile)
whose mothers were randomized to the placebo group had a mean (SE) DBP of 64.7 (1.23) mm Hg
compared with children who were obese or overweight in the DHA group (59.76 [0.91]), a difference
of 4.97 mm Hg. The analysis also yielded a statistically significant main effect for child age as DBP,
like SBP, was higher at 5.5 years of age than at any other age. For example, mean (SE) DBP at 5.5 years
in overweight condition and obese children in the placebo group was 69.8 (2.4) compared with 4,
4.5, 5 and 6 years (62 [2.3], 66.5 [1.8], 60.9 [2.3], and 63 [1.3], respectively). Higher maternal BMI
appeared to be associated with higher DBP (DBP: r = 0.216; P = .01). The DBP and variability by
randomization and weight status for each age are shown in Figure 2B.
Discussion
The prevalence of high BP during childhood is on the rise, partly owing to the high rates of obesity
during childhood. A study of more than 20 000 US children aged 2 to 17 years found 36% had high
BP (>90th percentile for weight, age, and height) at least once in a year.11 A meta-analysis found that
BP in childhood tracks to BP in adulthood12 and that higher BP in childhood is associated with risk
for hypertension in adulthood.13 Some of us began measuring childhood BP in 2010 as part of
monitoring the overall health of children born to women in the KUDOS trial and because a report of
early postnatal DHA supplementation5 linked lower BP at age 6 years to higher DHA exposure.
Subsequent reports from the Netherlands3,4 associating prenatal DHA exposure with lower
Table 2. Systolic and Diastolic Blood Pressure as a Function of Maternal DHA Randomization
and 5-Year Weight Status
Blood Pressure









Sample size, No. (%) 20 (24) 62 (76) 32 (36) 57 (64)
Systolic, mm Hg,
mean (SE)
104.28 (1.37) 99.43 (0.75) 100.34 (1.02) 99.30 (0.71)
Diastolic, mm Hg,
mean (SE)
64.73 (1.23) 60.70 (0.67) 59.76 (0.91) 59.48 (0.64)
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); DHA, docosahexaenoic acid.
a These values represent the interaction between
randomization group and weight status. The P for
interactions = .04 for systolic blood pressure and P
for interactions = .01 for diastolic blood pressure.
b Individual value for SBP and DBP of the placebo
group with BMI greater than the 85th percentile
differs from the 3 other groups (P < .05).





























Child systolic blood pressure variabilityA
65.554.54
Placebo group: ≤85th percentile BMI
Placebo group: >85th percentile BMI
DHA group: ≤85th percentile BMI



















Child diastolic blood pressure variabilityB
65.554.54
BMI indicates body mass index. Error bars indicate SE
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childhood BP supported our hypothesis that children of women randomized to DHA
supplementation would have lower BP.
We found a statistically significant difference in DBP, which was lower in the DHA group
compared with the placebo group; however, childhood weight status emerged as a major factor in
both SBP and DBP. In the mixed model analysis that included influential covariates, it became clear
that the advantages from maternal DHA supplementation accrued only to children at risk for
elevated BP owing to obesity or overweight condition. Both SBP and DBP showed a substantial
interaction between maternal DHA randomization and child weight status, suggesting that maternal
DHA supplementation exerted a protection for offspring who became overweight or obese in
childhood. The increase in BP among children who were obese or overweight in the placebo group
compared with the DHA group was large (3.94 mm Hg for SBP vs 4.97 mm Hg for DBP) and
statistically significant. Although we knew that obesity or overweight condition is associated with
higher BP in adults and children, we did not hypothesize a priori that children who were overweight
or obese as a group would gain an advantage from intrauterine exposure to DHA.
We chose weight status at 5 years of age for the mixed model analysis as the midpoint in the
ages of assessment. We realized that the weight status of individual children may have changed
between 4 and 6 years of age, but the BMI of subgroups varied little among ages 4, 5, and 6 years as
shown in Table 1. In fact, the groups who were obese or overweight at 5 years of age already had a
higher BMI by 2 years of age than did their leaner counterparts from the same prenatal
randomization. We doubt we would have observed an association between DHA supplementation
and childhood BP had the incidence of overweight condition and obesity not been so high (29%) in
this cohort of children. Nevertheless, the incidence is not markedly discrepant from the base rate in
children in general in the United States, in which 1 in 5 school-aged children is obese.14
Forsyth et al5 did not report BMI or state that they adjusted for child BMI in their analysis. They
reported 2.3 mm Hg lower SBP and 3.6 mm Hg lower DBP at 6 years of age in children randomized
to a formula containing DHA for the first several months of life. If our findings are correct that the
advantage of DHA supplementation for BP occurs only in children who are obese or overweight, we
speculate that the Forsyth et al5 cohort may also have had a high proportion of children with
overweight condition or obesity. Children in the Generation R study3 (n = 4455) were leaner than the
children in our cohort: their mean BMI was just above the 50th percentile (actual BMI, 15.8; range,
13.6-21.2) at 6 years of age, whereas the mean BMI in this secondary analysis exceeded the 60th
percentile at all ages. The authors of the Generation R study3 adjusted for BMI in linear regression
models and still observed a substantial association between maternal ω-3 status and BP; however,
the difference in BP was quite small.
Although smoking was variable within the subgroups, the mean number of smoking days during
pregnancy appeared higher in mothers whose children were obese or overweight in both maternal
randomizations. Maternal smoking appears to be associated with childhood obesity as has been
shown previously.15-18
It is important to consider that the protection against BP in children who are obese or
overweight during the preschool- and early school–aged periods is the result of a relatively brief
intervention that occurred as much as 6 years earlier. A persistent physiological implication after an
intrauterine intervention supports early developmental programming. Hypotheses derived from the
Developmental Origins of Health and Disease model posit that less-than-optimal conditions or
events experienced in utero are linked to adult disorders, including hypertension.
Furthermore, it is generally accepted that less-than-optimal in utero events do not necessarily
result in adverse physiological outcome. Nordling19 first proposed a theory for cancer that
Knudson20 termed a 2-hit or multiple-hit hypothesis. The hypothesis, then adopted by Li et al21 in
relation to the Developmental Origins of Health and Disease model, is that in utero insults may only
manifest as disease after a physiological second hit. Intrauterine malnutrition is a developmental
insult. In the case of our findings, we suggest that less-than-optimal development of some organ
system or systems associated with poor maternal DHA status is the first hit, which manifests as
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higher BP after the second hit of childhood overweight condition or obesity. We cannot know the
biological mechanism, but evidence from 2 trials of DHA supplementation during pregnancy
suggests 2 plausible mechanisms: intrauterine DHA resulted in more mature fetal autonomic nervous
system22 and reduced cortisol response to a stressor in infancy.23 If these effects were prolonged
after birth, either one could affect childhood BP.
Our results suggest an advantage of increased intrauterine DHA exposure to programming of
BP response to excess body weight. The children studied in these trials were all fed human milk (a
source of DHA) or infant formula with DHA (DHA was added to US formulas after 2002) exclusively
or in combination. Consequently, we interpret these findings as an advantage of intrauterine DHA
exposure for childhood BP. In the only other randomized clinical study that measured childhood BP
after exposure to DHA early in development, Forsyth et al5 found that infants who were fed a formula
with DHA for the first 4 months of life had lower SBP and DBP at age 6 years. Their results suggest
that DHA exposure can program lower childhood BP for at least some period after birth.
The absolute SBP and DBP for the 4 randomization-weight status groups are shown in Figure 2.
In searching the literature, we were unable to find chronological reports of BP in children at these
ages. We believe these results may be of interest to those who will study BP in young children in
the future.
Limitations
A limitation of the study is that mothers in the placebo group with children who were overweight or
obese provided a fewer number of days of human milk, and their children consumed more sodium
than did children who were overweight or obese in the DHA group. Although these subgroup
differences were clearly not statistically significant because of large SDs, they do suggest that
subgroups of children may not be entirely comparable. Consequently, they limit the conclusion that
DHA alone mitigated the association between overweight or obese weight status and childhood BP.
The generalizability of this secondary analysis may be limited to children of mothers expected to
have a healthy pregnancy and not be morbidly obese.
Conclusions
Children of women randomized to DHA supplementation compared with those randomized to
receive placebo during pregnancy appeared to be protected against the increase in SBP and DBP
associated with childhood overweight condition and obesity.
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